TP53 and serous adenocarcinoma: In contrast, type 2 is associated with estrogen independency, endometrial atrophy, and poor prognosis, and comprises various minor subtypes including serous carcinoma, clear cell carcinoma, and carcinosarcoma (CS), with high mutation rates in TP53 (60–91%) [7,8,].